PRZOOM - /newswire/ -
Cambridgeshire, United Kingdom, 2010/04/01 - Quotient Bioresearch ("Quotient"), announces a new educational webinar series entitled "14C Enabled Drug Development in Pharmaceutical R&D".
Quotient Bioresearch ("Quotient"), a leading provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide, announces a new educational webinar series entitled "14C Enabled Drug Development in Pharmaceutical R&D." The webinars will consist of scientific presentations from industry experts focused on a broad range of drug development activities that can be enhanced by 14C radiolabelled studies.
The webinar series begins April 27 and runs during May and early June 2010.
Each of the four webinars will cover specific topics: Metabolism; Species and Interspecies Dependent Metabolism; ivPK and Absolute Bioavailability; and Quotient's new Synthesis-to-Clinic platform. All four webinars are free of charge to attend and will also be available to view on demand after the event.
Each webinar will run twice a day at the following times:
7am and 9am Pacific Time/ 10am and 12pm Eastern Time/ 3pm and 5pm UK
Webinar 1: Metabolism, Tuesday 27 April
Professor Tom Baillie, Dean of the School of Pharmacy at the University of Washington and formerly Global VP Drug Metabolism and Pharmacokinetics with Merck, will discuss how the FDA MIST and ICH M3(r2) guidelines encourage metabolism investigations earlier than ever in drug development. The presentation will look at how industry is approaching this through innovative study designs and use of new technologies such as AMS (Accelerator Mass Spectrometry) and Orbitrap to enhance the information that can be generated during metabolism studies. The webinar will explore future approaches to conducting metabolism studies.
Webinar 2: Inter and Intra-species Differences in Drug Metabolism, Tuesday 11 May
Professor Alan Rettie, Chairman, Department of Medicinal Chemistry, University of Washington, will explore the impact of inter-species differences on metabolism studies and the impact of inter-species genetic polymorphisms on metabolism. The presentation will also provide case studies to highlight notable cases of metabolism directing the individual response.
Webinar 3: ivPK & Absolute Bioavailability, Tuesday 25 May
Dr. Bob Ings, RMI Pharmacokinetics & ex VP DMPK Roche Palo Alto, will illustrate how the routine use of iv microtracer dosing can enhance drug development and discuss what the data offer in terms of understanding absolute bioavailability, clearance characteristics and drug performance.
Webinar 4: Synthesis-to-Clinic Platform, Tuesday 8 June
The final presentation will explain how the themes discussed in the first three webinars can be comprehensively addressed by the services available through Quotient's Synthesis-to-Clinic platform. Case histories will be used to showcase recent applications of the Synthesis-to-Clinic platform and there will also be a Q&A of key topics of interest raised throughout the webinar series.
Quotient's innovative Synthesis-to-Clinic capability is a fully integrated service built on best-in-class technologies and capabilities from custom synthesis of radiolabelled compounds through to drug metabolism and clinical ADME studies. This integrated service simplifies the procurement of regulatory and non-regulatory studies, resulting in shorter development times and efficiencies. The complete project is coordinated through a single project manager, removing an extensive vendor management burden.
Orbitrap is a registered trademark of Thermo Fisher Scientific.
About Quotient Bioresearch
Quotient (quotientbioresearch.com) is a leading provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide. The company offers a unique range of drug development services through its three key focus areas - Chemistry & Metabolism, Bioanalytical Sciences and Clinical. Quotient has grown rapidly in the past three years, through a combination of both acquisition-led and organic growth. Quotient Bioresearch is part of Quotient Bioresearch Group, which comprises Quotient Bioresearch and HFL Sport Science.
For further press information please contact: Sarah Evans - The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom. T: +44 1477 539 539 F: +44 1477 539 540 E: quotient[.]scottpr.com.